Jocelyn Leiske

Title: Jocelyn Leiske: Innovator in Antibody Conjugation Technology

Introduction

Jocelyn Leiske is a prominent inventor based in Bothell, WA (US). She has made significant contributions to the field of biotechnology, particularly in the development of modified antibodies for therapeutic applications. Her innovative work has led to the creation of a patent that enhances the efficacy of antibody-drug conjugates.

Latest Patents

Jocelyn holds a patent titled "Cysteine mutated antibodies for conjugation." This invention provides modified heavy chain constant regions that include a cysteine at position 295 by EU numbering and optionally at position 239 by EU numbering. These cysteine residues create sites for conjugation to a drug or label. When both cysteines are present in a normal heterodimeric antibody format, there are four such sites per molecule of antibody, allowing a stoichiometry of one molecule of antibody to four of drug or label. The selection of the cysteine at position 295, with or without cysteine at position 239, is advantageous due to ease of expression, stability, and reduced cytotoxicity.

Career Highlights

Jocelyn is currently employed at Seagen Inc., a leading biotechnology company focused on developing innovative therapies for cancer treatment. Her work at Seagen has positioned her as a key player in the advancement of antibody-drug conjugates, which are crucial in targeted cancer therapies.

Collaborations

Throughout her career, Jocelyn has collaborated with notable colleagues, including Andrew Waight and Chris Leiske. These collaborations have fostered a productive environment for innovation and have contributed to the success of her projects.

Conclusion

Jocelyn Leiske's contributions to the field of biotechnology, particularly through her patent on cysteine mutated antibodies, highlight her role as an innovator in antibody conjugation technology. Her work continues to impact the development of effective cancer therapies.